Designing Decentralised Clinical Trials for Patient Diversity
Data shows that most DCT approaches significantly improve patient diversity. This analysis examines what the evidence means for clinical trial design strategy.
Articles, expert interviews, and insights from life sciences leaders
AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Read interview: How AI Is Reshaping Data Integrity in Pharma Manufacturing
Read interview: AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Read interview: AI in Pharma: Hype vs. What Actually Works
Read interview: How Pharmacy Innovation Is Changing Healthcare Delivery
Read interview: The Role of Regulatory Leadership in Healthcare
Read interview: Healthcare Supply Chains in Africa: Lessons from COVID-19
Read interview: How Cortical Implants Are Opening a New Era of Vision Restoration
Read interview: How Clinical Research Shapes Cardiac Device Innovation
Exclusive Pharmatica Content
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
Why Precision Alone Isn't Enough in Oncology Drug Discovery
Precision alone isn’t enough in oncology drug discovery. See why execution, biomarkers, and trial design determine scalable success in precision medicine.
Select the Right Data Collection Method for Real-World Evidence
Choosing the wrong RWE data source undermines your regulatory strategy. This framework helps pharma leaders select the right real-world data collection method based on your programme’s research question.
Drug Discovery and Pharmacoinformatics in 2026
Pharmacoinformatics is redefining drug discovery strategy. This analysis covers the AI platforms, molecular design tools, and regulatory frameworks shaping R&D pipelines in 2026.
Seven Ways AI Is Solving Pharmaceutical Supply Chain Problems
AI is tackling the pharmaceutical supply chain's most persistent problems, from demand forecasting to counterfeit detection. See the top 7 ways AI is improving supply chain resiliency.
Decentralised Clinical Trials: Balance Innovation and Integrity
Decentralised clinical trials expand access and reduce patient burden. Learn how sponsors balance innovation in DCT design, data integrity, and regulatory compliance.
What 13 Years of Data Shows About Drug Innovation in Psychiatry
From 2012 through 2024, the FDA only approved 22 drugs for the treatment of psychiatric conditions. Pharma R&D teams must rethink development strategies to unstall drug innovation in psychiatry
What Pharma R&D Tech Investment Committees Actually Fund
What do pharma R&D tech investment committees really fund? Learn how workflow fit, enterprise pull, and strategic relevance drive adoption.
Modern Drug Discovery Challenges Demand a New Pharma Paradigm
Explore the biggest drug discovery challenges facing pharma today, from translational gaps to AI integration, and why a new pharma paradigm is needed.
Preclinical vs Clinical Research Strategy for Drug Development
Explore the critical differences between preclinical vs clinical research, and how closing the translation gap can reduce drug development attrition and improve R&D decision-making.
Why the U.S. Medicine Supply Chain Is One Shortage Away from Crisis
The USP's 2025 Vulnerable Medicines List flags 100 drugs at high risk. Here is what to do to build pharma supply chain resilience.
Strategic Pharma Intelligence Drives Better Decisions in Life Sciences
Find out why strategic pharma intelligence is needed to connect insights and to guide confident decision-making across the drug development lifecycle.
